Document is current
Any future updates will be listed below
-
Authors
Nishiwaki, Satoshi https://orcid.org/0000-0002-6430-8958
Sugiura, Isamu
Fujisawa, Shin
Hatta, Yoshihiro
Atsuta, Yoshiko
Doki, Noriko
Kurahashi, Shingo
Ueda, Yasunori
Dobashi, Nobuaki
Maeda, Tomoya
Matsumura, Itaru
Tanaka, Masatsugu
Kako, Shinichi
Ichinohe, Tatsuo
Fukuda, Takahiro
Ohtake, Shigeki
Ishikawa, Yuichi
Miyazaki, Yasushi
Sakaida, Emiko
Maeda, Yoshinobu
Yamauchi, Takahiro
Kiyoi, Hitoshi
,
-
Funding
Funding for this research was provided by:
JSPS KAKENHI (JP 25K11666)
Japanese Society of Hematology
Japan Agency for Medical Research and Development (JP 22ck0106624h0003)
- License Information
-
More Information
Article History
Received: 6 June 2025
Revised: 21 August 2025
Accepted: 21 August 2025
First Online: 27 August 2025
Declarations
:
: S.N. reports honoraria from Otsuka Pharmaceutical Co. Ltd. S.F. reports honoraria from Bristol-Myers-Squibb, Nippon Shinyaku, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Novartis Pharma KK, Janssen, Kyowa Kirin Co., Ltd., AstraZeneca, CSL Behring K.K, Meiji Seika Pharma, AbbVie Inc, Takeda Pharmaceutical Co., Ltd., Asahi Kasei Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Kissei, Pharma Essentia Japan, Genmab, Argenx Japan, Alexion Pharma, Inc., and Chugai Pharmaceutical Co., Ltd. and research funding from Shionogi Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Asahi-Kasei Pharma, and Daiichi Sankyo Co., Ltd. Y.H. reports honoraria from Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and Novartis Pharma KK., and speakers bureau from Kyowa Kirin Co., Ltd. Y.A. reports honoraria from Novartis Pharma KK., Kyowa Kirin Co., Ltd., Abbvie GK, Astellas Pharma Inc., Mochida Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd. Y.U. reports honoraria from Otsuka Pharmaceutical Co., Ltd., and Sanofi K.K. N.Dobashi paid expert testimony from Otsuka Pharmaceutical Co., Ltd. T.M. reports research funding from Chugai Pharmaceutical Co., Ltd., and Sumitomo Pharma Co., Ltd., and honoraria from CSL Behring K.K, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Abbvie GK, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma KK., Pfizer Inc., Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Becton Dickinson Company, PharmaEssentia Japan KK and TOPPAN Holdings Inc. I.M. reports honoraria from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Novartis Pharma KK., Bristol-Myers Squibb, and AstraZeneca plc., research funding from Chugai Pharmaceutical Co., Ltd., Abbvie GK, Genmab K.K., Novartis Pharma KK, and Incyte Japan, and scholarship funds from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., Asahi Kasei Corporation, Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Abbvie GK. S.Kako reports honoraria from Chugai Pharmaceutical Co., Ltd., Sanofi K.K. and Pfizer Inc. Y.Miyazaki is an Associate Editor for the IJH and reports research funding from Nippon Shinyaku Co., Ltd., Novartis Pharma KK., Abbvie GK, Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., SymBio Pharmaceuticals Ltd., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Kyowa Kirin Co., Ltd., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., and Celgene Corp., and honoraria from Sumitomo Dainippon Pharma Co., Ltd. H.K. reports research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Perseus Proteomics Inc., CURED Co., Ltd., Astellas Pharma Inc., Asahi Kasei Corporation, Abbvie Inc., Nippon Shinyaku, Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Takeda Pharmaceutical Co. Ltd., and honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Abbvie Inc., Nippon Shinyaku Co., Ltd., AstraZeneca plc., Novartis Pharma KK., SymBio Pharmaceuticals Ltd.., Bristol-Myers Squibb K.K., Amgen Inc., Meiji Seika Pharma Co., Ltd., Pfizer Inc., Nippon Kayaku Co., Ltd., and Towa Pharmaceutical Co., Ltd. The remaining authors declare no competing financial interests.
